Limited Submission Opportunities
(Applications through UCSF Limited Submission Program)
- Pre-app deadline: Feb 13, 2023
New York Academy of Sciences Innovators in Science Award: Cancer Immunology
Aims to recognize bold, creative scientists seeking to increase our molecular and immunological understanding of cancer and inform novel therapeutic approaches. - Pre-app deadline: Feb 13, 2023
Breast Cancer Alliance Grants
Accepting applications for Young Investigator Grant and Exceptional Project Grant. - Extended deadline: Feb 28, 2023
NIH NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00)
Note: ONLY Cancer Control Science still open - Extended deadline: Feb 28, 2023
NIH NCI Cancer Screening Research Network (UG1)
Note: ONLY Statistics & Data Management Center and Coordinating & Communication Center still open
Intramural Funding Opportunities
- Deadline: Feb 1, 2023
The Cancer League RFA
The Helen Diller Family Comprehensive Cancer Center has been invited by The Cancer League to submit requests for funding. The Cancer League’s primary interest is in funding projects in early stage research and/or supporting and assisting patients through their cancer journey. Their mission is to support the fight against cancer in such areas as early detection, education, patient care services and research for various types of cancer for men, women and children. - Deadline: Feb 1, 2023
UCSF Alpha Stem Cell Clinic (ASCC) 2023 Fellowship Program
Fellowship applications are now available for physician scientists who are committed to academic research careers discovering and translating novel applications of stem cell biology and regenerative medicine to clinical problems. Priority will be given to MDs* or MD/PhDs who are currently in or have recently completed clinical fellowship training and have commenced a clinical or translational laboratory project focused on stem cell biology at UCSF Health. Early stage junior faculty also are encouraged to apply. - Deadline: rolling submissions
University of California Hematologic Malignancies Consortium (UCHMC) RFA
The University of California Hematologic Malignancies Consortium is requesting submission of proposals within two potential areas of funding.- RFP A: UCHMC funds for Junior Faculty and Trainee Competitive Seed Grants
- RFP B: UCHMC funds for Clinical Trials Support
Foundations/Other Sources
- Deadline: Mar 1, 2023
Aging and Cancer Research RFA
The Samuel Waxman Cancer Research Foundation (SWCRF) and The Mark Foundation for Cancer Research are pleased to issue a joint Request for Applications (RFA) for collaborative projects to focus on Aging and Cancer. Projects must include collaborations between two laboratories with different but complementary expertise.
NIH Announcements
If you are a Cancer Center member who is interested in applying and receiving grant writing support, please contact Erin Bank.
-
Supplement for your NCI grant: Apply for Administrative Supplements to Support Cancer Disparity Collaborative Research (PAR-22-114)
If you are an investigator who holds an active and eligible NCI-funded award (parent grant), not focused on cancer disparities, and are interested in expanding your research in the cancer disparities arena through collaboration, you are eligible!
The HDFCCC is aligning resources around a new administrative supplement opportunity and needs to hear from interested applicants and potential collaborators in order to best support applications.
If you are interested, and meet the criteria for an applicant or collaborator, please indicate your interest by filling out this short form.
Please contact Kaya Balke ([email protected]) with any questions. YOU DO NOT HAVE TO IDENTIFY A COLLABORATOR OR COMMIT TO PARTICIPATE at this point. We are just getting a sense of interest. More information, including a directory of potential collaborators in the areas of cancer disparities to follow.
- NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)
- Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Not Allowed)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Clinical Trial Required)
- NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 - Independent Basic Experimental Studies with Humans Required)
- Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)
To view NCI funding opportunities, search here